- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
- MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.
“We’ve invested a lot in Remdesivir and we’ll continue to invest a lot,”. Gilead Sciences (GILD) CEO, Daniel O’Day said that aside from revenues, the most important thing that they are doing here is to bring a positive impact for the patients and for the world as a whole. In an interview with CNBC, he […]
Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences.
Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Half of the patients hospitalized with Covid-19 are receiving remdesivir, which is sold as Veklury, according to CEO Daniel O’Day.
Gilead Sciences Inc. updated its guidance for 2020 on Monday, raising its outlook for sales to reflect sales of COVID-19 treatment remdesivir, while narrowing and lowering the top end of its per-share outlook. In a statement released ahead of a presentation at J.P. Morgan's annual healthcare conference which is being held virtually this year, the company said it now expects per-share earnings to range from a loss of 8 cents to a profit of 2 cents, compared with earlier guidance for a loss of 25...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance.
In a note out Friday morning, Citi analyst Mohit Bansal says that weakness makes it a good time to buy.
Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.
Diodes Incorporated (Nasdaq: DIOD), today announced Brett Whitmire, Chief Financial Officer; Emily Yang, Sr. Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relations are scheduled to participate at the 23rd Annual Needham Growth Conference, which is being held as a virtual event. Management is scheduled to present at 9:15 a.m. ET on Thursday, January 14, 2021 and will be available throughout the day to host conference calls with investors participating in ...